Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 12/20 | 0.53 |
| ▸ | TOP2A | P11388 | 1/20 | 0.53 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.53 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.52 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6880793 | 0.92 | GSK3B (0.50) | STAT3GSK3BTOP2ATOP2BCACNA1F | |
| SCHEMBL1345146 | 0.91 | STAT3 (0.65) | STAT3GSK3BTOP2ATOP2BCACNA1F | |
| SCHEMBL9688633 | 0.90 | CACNA1F (0.49) | STAT3GSK3BTOP2ATOP2BCACNA1F | |
| SCHEMBL5704363 | 0.90 | GSK3B (0.51) | STAT3GSK3BTOP2ATOP2BCACNA1F | |
| SCHEMBL9268292 | 0.90 | STAT3 (0.51) | STAT3GSK3BTOP2ATOP2BCACNA1F | |
| SCHEMBL8111555 | 0.89 | STAT3 (0.56) | STAT3GSK3BTOP2ATOP2BCACNA1F | |
| SCHEMBL10594730 | 0.88 | STAT3 (0.55) | STAT3GSK3BTOP2ATOP2BCACNA1F | |
| SCHEMBL8129186 | 0.88 | STAT3 (0.58) | STAT3GSK3BTOP2ATOP2BCACNA1F | |
| SCHEMBL15929884 | 0.87 | TOP2A (0.48) | STAT3GSK3BTOP2ATOP2BCACNA1F | |
| SCHEMBL13483600 | 0.87 | STAT3 (0.52) | STAT3GSK3BTOP2ATOP2BCACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230058189-A1 | QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME | Frequency Therapeutics, Inc. (US) | 2023-02-23 | — | — | US | disclosed |
| EP-2013182-B1 | AMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN SEIYAKU KK (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-2383271-B1 | Aminoquinolones as GSK-3 Inhibitors | KYORIN SEIYAKU KK (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-8063221-B2 | Aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-22 | — | — | US | disclosed |
| EP-2383271-A1 | Aminoquinolones as GSK-3 Inhibitors | Kyorin Pharmaceutical Co., Ltd. (JP) | 2011-11-02 | — | — | EP | disclosed |
| EP-2383271-A1 | Aminoquinolones as GSK-3 Inhibitors | Kyorin Pharmaceutical Co., Ltd. (JP) | 2011-11-02 | — | — | EP | disclosed |
| US-20070254866-A1 | Aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1319656-B1 | A NEW PROCESS FOR PREPARING A QUINOLONE-CARBOXYLIC ACID | LYNCHEM CO LTD (CN) | 2006-08-23 | — | — | EP | disclosed |
| US-6699992-B2 | REACTING M-FLUOROACETOPHENONE COMPOUND WITH ALKYL CARBONATE; REACTING ESTER OBTAINED WITH ALKYL ORTHOFORMATE AND AMINE; CYCLIZATION IN BASE | LYNCHEM CO., LTD. (CN) | 2004-03-02 | — | — | US | disclosed |
| US-20030166936-A1 | Process for preparing a quinolone-carboxylic acid | LYNCHEM CO., LTD. (CN) | 2003-09-04 | — | — | US | disclosed |
| EP-0265230-B1 | SUBSTITUTED-6-FLUORO-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACIDS, DERIVATIVES THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUNDS, AND PROCESSES FOR PRODUCING THE COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1992-01-08 | — | — | EP | disclosed |
| EP-0221463-B1 | QUINOLINE DERIVATIVES AND PROCESSES FOR PREPARATION THEREOF | Dainippon Pharmaceutical Co., Ltd. (JP) | 1991-08-14 | — | — | EP | disclosed |
| EP-0390215-A2 | Quinolone derivatives and salts thereof, preparation process es thereof, and antibacterial agents containing the same | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1990-10-03 | — | — | EP | disclosed |
| EP-0172651-B1 | Substituted-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acids; substituted-5-amino-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acids; substituted-5-amino-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids; derivatives thereof; pharmaceutical compositions comprising the compounds; and processes for producing the compounds | WARNER-LAMBERT COMPANY (US) | 1990-02-07 | — | — | EP | disclosed |
| US-4886810-A | ANTIBACTERIAL | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1989-12-12 | — | — | US | disclosed |
| US-4822801-A | 4-oxo-1,4-dihydroquinoline-3-carboxylic acid derivative as antibacterial agents | WARNER-LAMBERT COMPANY (US) | 1989-04-18 | — | — | US | disclosed |
| US-4795751-A | 5-substituted-6,8-difluoroquinolines useful as antibacterial agents | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1989-01-03 | — | — | US | disclosed |
| EP-0265230-A1 | Substituted-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acids, derivatives thereof, pharmaceutical compositions comprising the compounds, and processes for producing the compounds | WARNER-LAMBERT COMPANY (US) | 1988-04-27 | — | — | EP | disclosed |
| EP-0221463-A2 | Quinoline derivatives and processes for preparation thereof | Dainippon Pharmaceutical Co., Ltd. (JP) | 1987-05-13 | — | — | EP | disclosed |
| EP-0172651-A1 | Substituted-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acids; substituted-5-amino-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acids; substituted-5-amino-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids; derivatives thereof; pharmaceutical compositions comprising the compounds; and processes for producing the compounds | WARNER-LAMBERT COMPANY (US) | 1986-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254866-A1 | Aminoquinolones as GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | STAT3 115/4885GSK3B 1/4885TOP2A 205/4885 |
| US-20030166936-A1 | Process for preparing a quinolone-carboxylic acid | CYP4B1, QPCT, NQO2 | STAT3 4231/4885GSK3B 4162/4885TOP2A 601/4885 |
| US-20230058189-A1 | QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME | DCX, NES, MCL1 | STAT3 499/4885GSK3B 1102/4885TOP2A 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.